Jiangsu Hengrui Medicine Stock Forecast for 2023 - 2025 - 2030
Updated on 04/20/2024
Jiangsu Hengrui Medicine Stock Forecast and Price Target
Jiangsu Hengrui Medicine's stock is projected to advance by 30.76% from the previous closing price if it reaches the average target of ¥54.50 by the year's end, as reputable analysts recently projected. This potential upside is calculated on a high-end estimate of ¥120.00 and a low-end estimate of ¥40.10. If you are interested in 600276 stock, it is important to also consider its competitors.
30.76% Upside
Jiangsu Hengrui Medicine Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Jiangsu Hengrui Medicine's Price has fallen from ¥68.75 to ¥0.00 – a 100.00% decrease. For the next year, analysts are expecting Fair Value to reach ¥66.53 – an increase of 100.00%. Over the next seven years, experts predict that Fair Value will grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 601607 Stock Forecast | Shanghai Pharmaceuticals Holdi... | Outperform |
18
|
¥17.79 | Buy/Sell | ¥20.67 | 23.66% |
| 600196 Stock Forecast | Shanghai Fosun Pharmaceutical ... | Outperform |
16
|
¥22.51 | Buy/Sell | ¥33.57 | 29.50% |
| 000999 Stock Forecast | China Resources Sanjiu Medical... | Buy |
18
|
¥59.25 | Buy/Sell | ¥65.95 | 5.99% |
| 874 Stock Forecast | Guangzhou Baiyunshan Pharmaceu... | Outperform |
16
|
HK$20.35 | Buy/Sell | HK$24.33 | 11.94% |
| 600079 Stock Forecast | Humanwell Healthcare (Group) | Buy |
0
|
¥19.61 | Buy/Sell | ¥32.49 | -100.00% |
Jiangsu Hengrui Medicine Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Jiangsu Hengrui Medicine's Revenue has fallen from ¥27.73B to ¥22.82B – a 17.72% decrease. For the next year, analysts are expecting Revenue to reach ¥27.21B – an increase of 19.25%. Over the next seven years, experts predict that Revenue will grow by 132.95%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 000513 Stock Forecast | Livzon Pharmaceutical Group | Outperform |
18
|
¥36.98 | Buy/Sell | ¥39.23 | 11.41% |
| 600812 Stock Forecast | North China Pharmaceutical Com... | - |
12
|
¥4.47 | Buy/Sell | ¥12.26 | -100.00% |
| 600664 Stock Forecast | Harbin Pharmaceutical Group | - |
11
|
¥2.80 | Buy/Sell | ¥0.00 | -100.00% |
.jpg)
Jiangsu Hengrui Medicine Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, Jiangsu Hengrui Medicine's Dividend per Share has grown from ¥0.17 to ¥0.20 – a 17.65% increase. In the following year, 13 experts forecast Jiangsu Hengrui Medicine's Dividend per Share will decrease by 5.00%, to ¥0.19. Over the next seven years, the forecast is for Dividend per Share to grow by 40.95%.
Jiangsu Hengrui Medicine EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Jiangsu Hengrui Medicine's EBITDA has gone down from ¥6.72B to ¥4.83B – a 28.12% drop. For next year, analysts predict EBITDA of ¥6.22B, which would mean an increase of 28.77%. Over the next seven years, experts predict that Jiangsu Hengrui Medicine's EBITDA will grow at a rate of 65.01%.
Jiangsu Hengrui Medicine EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Jiangsu Hengrui Medicine's EBIT has fallen from ¥6.27B to ¥4.18B – a 33.42% decrease. In the next year, analysts believe that EBIT will reach ¥5.91B – an increase of 41.47%. For the next seven years, the forecast is for EBIT to grow by 432.56%.
Jiangsu Hengrui Medicine EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Jiangsu Hengrui Medicine's EPS has fallen from ¥0.93 to ¥0.00 – a 100.00% decrease. For the next year, analysts are expecting EPS to reach ¥0.90 – an increase of 100.00%. Over the next seven years, experts predict that EPS will grow by 100.00%.
Site Navigation
.jpg)